glioma
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
Brain Cancer Study Reveals Immune Cell Populations Linked to Aggressive Subtype
Researchers used single-cell RNA sequencing and spatial transcriptomics to find two myeloid-derived suppressor cell subsets supporting the growth of an aggressive glioblastoma.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
Glioma Organization Untangled Using Spatial Transcriptomic, Proteomic Profiles
Researchers saw disorganized and structured regions that appeared to reflect hypoxia conditions in glioma, along with five cell state layers within the structured parts of a tumor.
Datar Cancer Genetics Aims to Bring Circulating Glial Cell Assay to US to Aid Brain Cancer Diagnosis
Premium
The India-based firm expects to obtain regulatory clearance and launch its TriNetra-Glio test from its facility in North Carolina in the next two years.